Sigma Investment Counselors Inc. Sells 523 Shares of Cencora, Inc. (NYSE:COR)

Sigma Investment Counselors Inc. cut its position in shares of Cencora, Inc. (NYSE:COR) by 3.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 15,830 shares of the company’s stock after selling 523 shares during the quarter. Sigma Investment Counselors Inc.’s holdings in Cencora were worth $3,557,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Howard Capital Management Inc. boosted its stake in shares of Cencora by 31.5% in the 4th quarter. Howard Capital Management Inc. now owns 1,400 shares of the company’s stock worth $315,000 after buying an additional 335 shares during the last quarter. Abound Financial LLC purchased a new position in Cencora in the fourth quarter worth $477,000. Navellier & Associates Inc. boosted its position in Cencora by 3.8% in the fourth quarter. Navellier & Associates Inc. now owns 20,007 shares of the company’s stock worth $4,495,000 after purchasing an additional 730 shares during the last quarter. Greystone Financial Group LLC grew its stake in Cencora by 3.0% in the 4th quarter. Greystone Financial Group LLC now owns 3,255 shares of the company’s stock valued at $731,000 after purchasing an additional 96 shares during the period. Finally, Passumpsic Savings Bank increased its position in shares of Cencora by 1.5% during the 4th quarter. Passumpsic Savings Bank now owns 6,559 shares of the company’s stock valued at $1,474,000 after purchasing an additional 95 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Insider Transactions at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares of the company’s stock, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on COR shares. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Wells Fargo & Company boosted their target price on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. Robert W. Baird raised their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Evercore ISI upped their price objective on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Finally, Barclays increased their price objective on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $277.90.

Cencora Trading Down 0.8 %

Shares of COR stock opened at $241.47 on Friday. The stock has a market capitalization of $46.83 billion, a price-to-earnings ratio of 34.35, a PEG ratio of 1.31 and a beta of 0.49. The company’s fifty day simple moving average is $239.52 and its two-hundred day simple moving average is $237.45. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $262.26. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date of this dividend is Friday, February 14th. Cencora’s payout ratio is 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.